K Number
K023039
Device Name
BLOOD/SOLUTION ADMINISTRATION SET, MODEL 33.015
Date Cleared
2002-11-07

(56 days)

Product Code
Regulation Number
880.5440
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
Administration of Intravenous fluids and drugs. The Tuta Healthcare Pty. Limited Blood Administration Set is a device used to administer fluids, blood and blood products from a container to a patient's vascular system Through a catheter or venous access system inserted into a vein. Use of Needle-Free Access site may aide in the prevention of needlestick injury.
Device Description
The Tuta Healthcare Blood/Solution Administration Set is designed administer fluids from a container to a patient's vascular system through a needle catheter inserted into a vein. The pump helps to control the rate of flow of fluids from the container to the patient.
More Information

Not Found

No
The document describes a standard fluid administration set and pump, with no mention of AI or ML capabilities. The performance studies focus on flow rate and biocompatibility, not algorithmic performance.

No
The device is used for the administration of fluids, blood, and blood products to a patient, which is a supportive function rather than directly treating a medical condition.

No

Explanation: The device is used to administer fluids and drugs, control the flow rate, and prevent needlestick injuries. Its function is therapeutic/administrative, not to diagnose a condition.

No

The device description explicitly mentions a "Blood/Solution Administration Set" and a "pump" which are physical hardware components used to administer fluids. The performance studies also focus on flow rate testing of the physical set and biocompatibility of its materials.

No, this device is not an IVD (In Vitro Diagnostic).

Here's why:

  • Intended Use: The intended use is clearly stated as "Administration of Intravenous fluids and drugs" and "administer fluids, blood and blood products from a container to a patient's vascular system". This describes a device used on a patient for therapeutic or supportive purposes, not for testing samples from a patient to diagnose or monitor a condition.
  • Device Description: The description focuses on the mechanism of administering fluids into the vascular system, including the use of a pump to control flow rate. This aligns with a medical device used for treatment or support, not for diagnostic testing.
  • Lack of Diagnostic Elements: There is no mention of analyzing samples (blood, urine, tissue, etc.), detecting analytes, or providing information for diagnosis or monitoring.
  • Performance Studies: The performance studies described are related to flow rate and biocompatibility, which are relevant to the safe and effective administration of fluids, not to diagnostic accuracy.

IVD devices are used to examine specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes. This device's function is entirely focused on delivering substances into the body.

N/A

Intended Use / Indications for Use

Administration of Intravenous fluids and drugs.

The Tuta Healthcare Pty. Limited Blood Administration Set is a device used to administer fluids, blood and blood products from a container to a patient's vascular system Through a catheter or venous access system inserted into a vein.

Use of Needle-Free Access site may aide in the prevention of needlestick injury.

Product codes (comma separated list FDA assigned to the subject device)

BRZ

Device Description

Not Found

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

patient's vascular system

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Laboratory beach testing has been performed to assess the new device as compared to the devices proposed to be substantially equivalent, The testing included the following:

  • Flow rate testing of the Blood/Solution Administration Set as compared to . Baxter Healthcare's Solution Administration Set.

Additionally, biocompatibility testing, performed in accordance with the General Program Memorandum #G95 , has been conducted on all materials of the Blood/Solution Administration Set which are utilized in the fluid path.

Results from the biocompatibility testing have shown the materials of the Blood/Solution Administration Set are suitable for limited contact.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.

K924721

Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).

Not Found

§ 880.5440 Intravascular administration set.

(a)
Identification. An intravascular administration set is a device used to administer fluids from a container to a patient's vascular system through a needle or catheter inserted into a vein. The device may include the needle or catheter, tubing, a flow regulator, a drip chamber, an infusion line filter, an I.V. set stopcock, fluid delivery tubing, connectors between parts of the set, a side tube with a cap to serve as an injection site, and a hollow spike to penetrate and connect the tubing to an I.V. bag or other infusion fluid container.(b)
Classification. Class II (special controls). The special control for pharmacy compounding systems within this classification is the FDA guidance document entitled “Class II Special Controls Guidance Document: Pharmacy Compounding Systems; Final Guidance for Industry and FDA Reviewers.” Pharmacy compounding systems classified within the intravascular administration set are exempt from the premarket notification procedures in subpart E of this part and subject to the limitations in § 880.9.

0

11.0-510 (k) Summary

Safety and Tuta's of Effectiveness for Summary Blood/Solution Administration Set

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

Assigned 510(k) number K Od 3 o 3 9

1. Manufacturer's Name:Tuta Healthcare Pty. Limited
Manufacturer's Address318-332 Burnsbay Road
Lane Cove , Sydney NSW 2066
Australia
Contact Person:Omid Souresrafil PhD
Telephone Number:+ 61 2 94270300 (Switchboard)
  • 61 2 9429 6381 (Direct) |
    | Fax Number: | +61 2 9427 5017 |
    | Date: | 10/09/02 |
    | 2. Device Name:
    Trade Name:
    Proprietary Name:
    Classification Name: | Blood/Solution Administration Set
    Tuta Healthcare Blood/Solution Administration Set
    Administration Set, Intravascular as Per CFR 21 880.5440 |
    1. Legally Marketed Equivalent Device
      The, Blood/Solution Administration Set in the submission is substantially equivalent to Baxter Healthcare's Solution Administration Set (K924721).

The Tuta Healthcare Pty. Limited Blood Administration Set is a device used to administer fluids, blood and blood products from a container to a patient's vascular system Through a catheter or venous access system inserted into a vein.

Use of Needle-Free Access site may aide in the prevention of needlestick injury.

Description of the intended use of the Device

510 (k) Application - Blood/Solution Administration Set Tuta Healthcare Pty. Limited

1

The Tuta Healthcare Blood/Solution Administration Set is designed administer fluids from a container to a patient's vascular system through a needle catheter inserted into a vein. The pump helps to control the rate of flow of fluids from the container to the patient.

Summary of Similarities and Differences in Technological Characteristics, ব Performance and intended use

The 510(k) "Substantial Equivalence Decision Making Process (Detailed)" decision tree was utilized to make a determination of the substantial equivalence.

1. Does the new device have the same indication statement?

Yes. The Blood/Solution Administration Set and Baxter Healthcare's Solution Administration Set have the same indications for use being "administration of fluids from a container to a patient's vascular system through a needle catheter inserted into a vein.

2. Does the new device have the same technological characteristics, e.g. Design Materials.

Yes, The design of the Blood/Solution Administration Set and Baxter Healthcare's Solution Administration Set are similar in terms of components of , PVC tubing, roller regulators and perforators.

There are no differences in the principle of operation of the Blood/Solution Administration Set and Baxter Healthcare's Solution Administration Set.

3. Could the new characteristics Affect Safety or effectiveness?

No new characteristics.

4. Are the descriptive characteristics precise enough to Ensure equivalence?

Yes. The descriptive characteristics of the Tuta Healthcare Blood/Solution Administration Set and Baxter Healthcare's Solution Administration Set are enough to ensure equivalence.

5. Are performance data available to Assess Equivalence?

Yes. Laboratory beach testing has been performed to assess the new device as compared to the devices proposed to be substantially equivalent, The testing included the following:

  • Flow rate testing of the Blood/Solution Administration Set as compared to . Baxter Healthcare's Solution Administration Set.

2

Additionally, biocompatibility testing, performed in accordance with the General Program Memorandum #G95 , has been conducted on all materials of the Blood/Solution Administration Set which are utilized in the fluid path.

6. Does the Performance data demonstrate equivalence?

Yes. Based upon the results of the laboratory testing, the performance of the Blood/Solution Administration Set compares favourably to that of the current marketed Baxter Healthcare's Solution Administration Set.

Results from the biocompatibility testing have shown the materials of the Blood/Solution Administration Set are suitable for limited contact.

CONCLUSION:

Based upon the above information, the Blood/Solution Administration Set are substantially equivalent to Baxter Healthcare's Solution Administration Set.

3

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized caduceus symbol, which is a staff with two snakes entwined around it. The caduceus is positioned to the right of the text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA", which is arranged in a circular pattern around the left side of the logo.

Public Health Service

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

NOV 7 2002

Dr. Omid Souresrafil Tuta Healthcare Pty. Limited 318-332 Burns bay Road Lane Cove, Sydney NSW 2066 AUSTRALIA

Re: K023039

Trade/Device Name: Blood/Solution Administration Set Regulation Number: 880.5440 Regulation Name: Intravascular Administration Set Regulatory Class: II Product Code: BRZ Dated: September 10, 2002 Received: September 12, 2002

Dear Dr. Souresrafil:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

4

Page 2 - Dr. Souresrafil

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4618. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Timothy A. Ulatowski Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health

5

4. STATEMENT OF INDICTIONS FOR USE

K023039 510(k) Number (if known): ____________________________________________________________________________________________________________________________________________________

Device Name: Blood/Solution Administration Set

Indications For Use: Administration of Intravenous fluids and drugs.

The Tuta Healthcare Pty. Limited Blood Administration Set is a device used to administer fluids, blood and blood products from a container to a patient's vascular system Through a catheter or venous access system inserted into a vein.

Use of Needle-Free Access site may aide in the prevention of needlestick injury.

(PLEASE DO NCT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use fi (Per 21 CFR 801.109)

510 (k) Application - Blood/Solution Administration Set Tuta Healthcare Pty. Limited

8/8

Petura Church

(Division Sign-Off) Division of Anesthesiology, General Hospital, Infection Control, Dental Devices

510(k) Number: K023039